ZURA BIO LTD CLASS A (ZURA)
Health Care · Biotechnology · NASDAQ
Zura Bio is a clinical-stage biotechnology company pioneering bispecific antibody therapies to address significant unmet needs in complex autoimmune and inflammatory diseases.
What ZURA BIO LTD CLASS A does
Zura Bio is a clinical-stage biotechnology company focused on developing novel, dual-pathway antibody therapies for autoimmune and inflammatory diseases. Its lead candidate, tibulizumab, is a bispecific antibody targeting IL-17A and BAFF, currently in Phase 2 clinical trials for hidradenitis suppurativa and systemic sclerosis. The company also maintains a pipeline of early-stage monoclonal antibody candidates targeting IL-33 and the IL-7 receptor alpha chain.
Recent developments
Zura recently completed enrollment for its Phase 2 TibuSHIELD (HS) and TibuSURE (SSc) trials, with topline data expected in Q4 2026 and H1 2027, respectively. The company also announced plans to initiate a new Phase 2 trial for tibulizumab in polymyalgia rheumatica (PMR) by the end of 2026.
From ZURA BIO LTD CLASS A's filing of 2026-08-11.
Themes: Autoimmune and inflammatory diseases, Bispecific antibodies, Immunology, Pipeline-stage biotechnology
Fundamentals
- Price$5.71 as of 2026-09-09 close
- Market cap$547M as of 2026-08-11 (share count; price 2026-09-09)
- 1-year return+159.5% 2025-09-09 close $2.20 → 2026-09-09 close $5.71
- P/En/a negative earnings
- ROE-67.6% FY2025, SEC XBRL
- Debt / equity0.00 as of 2026-09-02
- Beta1.44 as of 2026-09-02
- Last reported earnings2026-08-11 SEC EDGAR Form 8-K (Item 2.02)
How ZURA compares in its sector
- return on equitybottom 25% 510 covered Health Care peers, as of 2026-09-02
- free cash flow (absolute dollars, latest fiscal year)middle range 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How ZURA BIO LTD CLASS A looks technically
ZURA BIO LTD CLASS A (ZURA) is trading 8.7% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 14 trading days ago — a "golden cross", a bullish long-term signal. A strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 26, with buyers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 49, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bearish about 1 trading day ago (its momentum flipped negative). It made a new 20-day high about 11 trading days ago. It is 23.3% below its highest point of the past year.
Trend
8
| Distance from the 200-day | it is trading 8.7% above its 200-day average, the long-term trend line — a longer-term uptrend | +8.8% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $5.59 | $5.59 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $5.25 | $5.25 |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing high 16 calendar days ago — the swings before that are what the structure reading is measured on | 16 sessions |
| Wave structure | its recent swings can be read as a completed three-part upward correction — a pullback in the A-B-C shape Elliott-wave chartists use; the labelling fails if price closes above 7.06. It is the only labelling that fits, and it describes the swings already printed, not what comes next. | possible three-wave upward correction, complete |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 14 trading days ago — a "golden cross", a bullish long-term signal | 14 sessions |
| Trend strength (14-day ADX) | a strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 26, with buyers in control | 26.2 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 49, neither overbought (above 70) nor oversold (below 30) | 49.1 |
|---|---|---|
| Position in its 14-day range | it is trading near the bottom of its 14-day range ($5.39 to $7.06) — its "stochastic" reading is 19 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 19.2 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bearish about 1 trading day ago (its momentum flipped negative) | 1 session |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $7.44 | $7.44 |
|---|---|---|
| From the 52-week high | it is 23.3% below its 52-week high (its highest price of the past year) | -23.3% |
| Above the 52-week low | it is 203.7% above its 52-week low (its lowest price of the past year) | +203.7% |
| Below the 52-week high | it is 23.3% below its highest point of the past year | 23.3% |
| Since a 20-day breakout | it made a new 20-day high about 11 trading days ago | 11 sessions |
| Since a 55-day breakout | it made a new 55-day high about 11 trading days ago | 11 sessions |
| All-time high | its highest closing price on record is $37.55 (set on 2023-03-24) | $37.55 |
| Given back of the 52-week move | over the past year its closes ranged ($1.90 to $7.04), and it has given back roughly a quarter of its rise from last year’s low — 26% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $3.70 to $3.86. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 25.9% |
| From the all-time high | it is 84.8% below its all-time high | -84.8% |
| Nearest price level | it is trading 0.6% below a resistance level at $5.75 — a price it turned at three times since 2026-01-02, most recently on 2026-07-21. Since 2024-09-09 it has 9 such levels below the current price and 2 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +0.6% |
| All-time low | its lowest closing price on record is $0.97 (set on 2025-04-04) | $0.97 |
| Above the all-time low | it is 488.7% above its all-time low | +488.7% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are narrower than usual versus its own recent 6-month history (tighter than about 79% of it) | 21st percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.396 between its high and its low — about 6.9% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.396 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $5.39 and $6.30 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $5.39 – $5.84 – $6.30 |
| Typical daily range (% of price) | its price moves about 6.9% in a typical session — more volatile than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 6.9% |
| Stretch from the 200-day average | it is trading 1.2 daily ranges above its 200-day average price (8.8% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 1.2 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.33× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | not available for this company yet | n/a |
Candlestick patterns
1
| Since a doji | 4 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 4 sessions ago |
|---|
Price gaps
3
| Gap at the open | it opened on 2026-09-09 1.5% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and had not traded back through that level by the close | -1.5% |
|---|---|---|
| Open gap | it gapped 3.0% below the previous close 9 sessions ago and has not traded back through the level it left behind at 6.32 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | -3.0% |
| Gap filled | a 2.6% gap up opened on 2026-08-19 has been "filled" 13 sessions ago — price traded back through the level the gap left behind, and it took 1 session to close | 13 sessions ago |
Price streaks
1
| Closing streak | it has closed lower 2 sessions in a row, a -8.35% move over the run — an unbroken run of down days, which describes what has already happened and says nothing about the next session | 2 sessions down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 2.9 percentage points (the stock lost 4.3% while the market lost 1.4%) | -2.9% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 58.6 percentage points (the stock gained 61.8% while the market gained 3.1%) | +58.6% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 31.3 percentage points (the stock lost 18.9% while the market gained 12.4%) | -31.3% |
| vs market, 12 months | over the past 12 months this stock beat the market by 142.3 percentage points (the stock gained 159.5% while the market gained 17.2%) | +142.3% |
Signal agreement
2
| Bullish technical signals | 5 of the 9 technical signals we can compute for it are currently in a bullish state: a strong uptrend, with buyers in control, a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, near the bottom of its 14-day range (oversold), trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 5 of 9 |
|---|---|---|
| Bearish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bearish state: MACD momentum is negative, lagging the market over 6 months — these describe past price behaviour, not a forecast | 2 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 7.0% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-08-03 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is thick, spanning 12.4% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | +7.0% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 5% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $5.45 — a volume-weighted average of daily closes over 167 sessions, not a true tick-by-tick VWAP. | +4.8% |
|---|---|---|
| Vs the average paid since it last reported | the price is 4% below the average price paid since it last reported on 2026-08-11 (its 10-Q), so the typical buyer over that stretch is under water. That average is $5.96 — a volume-weighted average of daily closes over 21 sessions, not a true tick-by-tick VWAP. | -4.2% |
Price levels it has turned at before
ZURA last closed at $5.71 on 2026-09-09. Since 2024-09-09 it has turned at 9 prices below its last close and 2 above; the 3 nearest below and the 2 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $5.75 | Resistance | 0.6% above the last close | turned there three times · 2026-01-02 to 2026-07-21 |
| $5.44 | Support | 4.7% below the last close | turned there twice · 2026-01-30 to 2026-08-14 |
| $6.01 | Resistance | 5.3% above the last close | turned there twice · 2026-07-01 to 2026-08-07 |
| $5.11 | Support | 10.6% below the last close | turned there twice · 2024-10-18 to 2026-04-21 |
| $4.85 | Support | 15.1% below the last close | turned there twice · 2024-11-11 to 2026-07-13 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a three-part upward correction — the A-B-C shape chartists use for a pullback — now complete.
This labelling fails — stops being a possible reading at all — if it closes above $7.06.
It is the only labelling that fits these swings, though its proportions are not the textbook ones.
This reading has stood for 1 trading day, since 2026-09-09.
Read from daily closes as of 2026-09-09.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Recent golden cross (50-day crossed above 200-day) · Pulled back from the 12-month high · MACD just crossed bearish (12/26/9) · in a strong, established uptrend (ADX) · lagging the market | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low
Based on daily closing prices as of 2026-09-09. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Mean price target$18.00 range $11.00 – $26.00
Analyst estimates, as of 2026-09-09. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for ZURA
- Consensus EPS estimate-$0.2033 next reporting period, as of 2026-09-09
- Readings revised upward0% of 3 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["The company has no approved products and has never generated revenue, making its financial future entirely dependent on the success of its clinical-stage product candidates.","The drug development process is lengthy, expensive, and subject to significant regulatory uncertainty, with no guarantee that any of its current clinical trials will achieve their primary endpoints or receive marketing approval."]
What changed in the latest 10-Q
AI-assisted comparison of ZURA's 10-Q filed 2026-05-07 against the prior one filed 2025-11-13.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing references audited consolidated financial statements as of December 31, 2025 (vs. December 31, 2024 in older filing)
- Newer filing states net loss for three months ended March 31, 2026 was $24.2 million (vs. $17.4 million for March 31, 2025)
- Newer filing states accumulated deficit of $248.8 million as of March 31, 2026
- Newer filing states aggregate gross proceeds raised of approximately $421.5 million as of filing date
- Newer filing changes TibuSHIELD expected topline results timing to fourth quarter of 2026 (vs. third quarter of 2026 in older filing)
- Newer filing changes participant count in TibuSHIELD to approximately 225 participants (vs. approximately 180 in older filing)
- Newer filing changes TibuSURE expected topline results timing to first half of 2027 (vs. fourth quarter of 2026 in older filing)
- Removed:
- Older filing described company as 'clinical-stage, multi-asset immunology company' with 'strategic focus to harness dual-pathway biology' - newer filing uses simpler description as 'clinical-stage biotechnology company'
- Older filing stated 'Three Phase 1/1b clinical studies evaluating tibulizumab have been completed' - newer filing removes this reference
- Older filing included disclosure about monitoring timelines and strategy in TibuSHIELD study in light of competitive landscape - newer filing removes this monitoring language
- Older filing included disclosure about monitoring timelines and strategy in TibuSURE study - newer filing removes this monitoring language
- Older filing described crebankitug with extensive detail about IL-7 and TSLP pathways and three Phase 1/1b studies - newer filing shortens description
- Older filing included extensive detail on torudokimab development and competitive landscape with Phase 2b/3 trial results from other companies - newer filing removes competitive analysis details
- Older filing included incorporation date and subsidiary formation details - newer filing removes this information
- Older filing text appears truncated at end; newer filing text also truncated but at different point
- Reworded:
- Tibulizumab description changed from targeting 'interleukin-17A (IL-17A) and B-cell activating factor' to 'interleukin-17 and B-cell activating factor'
- Overview section rewritten: removed 'multi-asset' descriptor and 'dual-pathway biology' strategic focus language
- Tibulizumab description changed from 'demonstrates potential in mitigating chronic inflammation while preserving the integrity of the immune system' to focus on being 'designed to neutralize' the cytokines
- Crebankitug description condensed: removed 'high affinity' descriptor and detailed pathway discussion, changed from 'actively assessing competitive landscape' to simply 'assessing potential therapeutic indications'
- Torudokimab description shortened: removed references to RAGE pathway, removed competitive landscape discussion and specific mentions of other companies' trial results
- Notes:
- Both filings appear truncated at the end of the provided text, limiting complete comparison of full MD&A sections
- Comparison is limited to the portions of text provided; full MD&A sections may contain additional changes not visible in these excerpts
Risk Factors
The two filings could not be meaningfully compared for this section.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales are on record for ZURA — recent Form 4 activity was compensation-related (awards, option exercises, or tax withholding), not open-market buying or selling.
View full insider trading history → View SEC Form 3/4/5 filingsOnly open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Short interest (FINRA)
ZURA had 11,440,748 shares of reported short interest as of the 2026-08-14 FINRA settlement date (delayed, bi-monthly; not real-time).
ZURA had 11.9% of its shares outstanding sold short as of the 2026-08-14 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 12.86 days to cover at the same settlement.
- Reported short interest (shares) 11,440,748
- Short interest (% of shares outstanding) 11.9%
- Prior settlement (shares) 10,513,220
- Reported change 8.82%
- Days to cover (reported) 12.86
Reported to FINRA as of the 2026-08-14 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- AbbVie (ABBV)
- Amgen (AMGN)
- Eli Lilly (LLY)
- Novartis (NVS)
- Regeneron Pharmaceuticals (REGN)
- Sanofi (SNY)
- Ucb SA (UCBJY)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare ZURA vs…
ZURA BIO LTD CLASS A is found in…
Frequently asked questions
What does ZURA BIO LTD CLASS A (ZURA) do?
Zura Bio is a clinical-stage biotechnology company focused on developing novel, dual-pathway antibody therapies for autoimmune and inflammatory diseases. Its lead candidate, tibulizumab, is a bispecific antibody targeting IL-17A and BAFF, currently in Phase 2 clinical trials for hidradenitis suppurativa and systemic sclerosis. The company also maintains a pipeline of early-stage monoclonal antibody candidates targeting IL-33 and the IL-7 receptor alpha chain.
What sector is ZURA BIO LTD CLASS A (ZURA) in?
ZURA BIO LTD CLASS A (ZURA) is classified in the Health Care sector. Its industry is Biotechnology. It trades on NASDAQ.
Who are ZURA BIO LTD CLASS A's (ZURA) competitors?
Notable peers of ZURA BIO LTD CLASS A (ZURA) include AbbVie, Amgen, Eli Lilly, Novartis and Regeneron Pharmaceuticals. This peer set is informational only — not financial advice.
Is ZURA BIO LTD CLASS A (ZURA) overbought or oversold right now?
ZURA BIO LTD CLASS A (ZURA) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 49, in the neutral middle (as of 2026-09-09). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on ZURA come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest; prices are market data, as of 2026-09-02; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-09-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.